http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#Head http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#assertion http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#provenance http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#pubinfo http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#assertion http://purl.obolibrary.org/obo/DOID_5408 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_5408 http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00630 http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#association http://www.w3.org/2000/01/rdf-schema#label alendronate sodium tablets usp are a bisphosphonate indicated for treatment and prevention of osteoporosis in postmenopausal women 1 1 1 2 treatment to increase bone mass in men with osteoporosis 1 3 treatment of glucocorticoid induced osteoporosis 1 4 treatment of paget s disease of bone 1 5 limitations of use optimal duration of use has not been determined for patients at low risk for fracture consider drug discontinuation after 3 to 5 years of use 1 6 alendronate sodium tablets usp are indicated for the treatment of osteoporosis in postmenopausal women in postmenopausal women alendronate sodium tablets usp increase bone mass and reduces the incidence of fractures including those of the hip and spine vertebral compression fractures see clinical studies 14 1 alendronate sodium tablets usp are indicated for the prevention of postmenopausal osteoporosis see clinical studies 14 2 alendronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 14 3 alendronate sodium tablets usp are indicated for the treatment of glucocorticoid induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7 5 mg or greater of prednisone and who have low bone mineral density see clinical studies 14 4 alendronate sodium tablets usp are indicated for the treatment of paget s disease of bone in men and women treatment is indicated in patients with paget s disease of bone who have alkaline phosphatase at least two times the upper limit of normal or those who are symptomatic or those at risk for future complications from their disease see clinical studies 14 5 the optimal duration of use has not been determined the safety and effectiveness of alendronate sodium tablets usp for the treatment of osteoporosis are based on clinical data of four years duration all patients on bisphosphonate therapy should have the need for continued therapy re evaluated on a periodic basis patients at low risk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture re evaluated periodically http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00630 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#provenance http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#pubinfo http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#sig http://purl.org/nanopub/x/hasSignature BOQ6C12YIHK6l2Jyzzm9grRjA5lBJJvLVU5lJwLAyaiVnwlFc0tlpoTA5K2r46/BFR2IK5xLSVffIyEMM3lHkBMLyMsDxcPGiEvM1LohjrBKTvnr3R2qhkOqIedn7qpNK8GUsnxG57XCPWuPDVEF/ViXjnPlLjbvnw1eX2601mI= http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk http://purl.org/dc/terms/created 2021-06-30T09:16:32.903+02:00 http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA7gbqitc-KeRRjYM70h-y81hRQXqEaPNucGKpP5Zbfqk https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs